scholarly journals Qi-Regulating and Blood Circulation-Promoting Therapy Improves Health Status of Stable Angina Pectoris Patients with Depressive Symptoms

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Xiao-Reng Wang ◽  
Dan-Dan Song ◽  
Tian-Qi Tao ◽  
Tao He ◽  
Xu-Dong Wu ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Health Status ◽  
Chinese Medicine ◽  
Angina Pectoris ◽  
Traditional Chinese Medicine ◽  
Stable Angina ◽  
Blood Circulation ◽  
Stable Angina Pectoris ◽  
Atp Levels ◽  
Specific Health

Depressive symptoms have been found to be highly prevalent among patients with coronary heart disease (CHD) and seriously affect the patients’ quality of life. However, most psychotropic drugs have warnings about potential side effects. Accordingly, safer effective alternatives are urgently demanded. Angina pectoris of CHD is considered as “chest stuffiness and heartache syndrome” in traditional Chinese medicine, with the major syndrome type named Qi stagnation and blood stasis. Qi-regulating and blood circulation-promoting therapy has increasingly shown unique advantages in CHD patients. This study investigated the efficacy of Xuefu Zhuyu decoction, a representative prescription of Qi-regulating and blood circulation-promoting therapy, on angina pectoris patients with depressive symptoms. Depressive symptoms were stratified at baseline in 30 patients with stable angina pectoris who participated in both baseline and 12-week follow-up studies. After performing a stratified analysis, the angina pectoris-specific health status and traditional Chinese medicine “chest stuffiness and heartache syndrome” were evaluated by self-reports using the associated questionnaire scales, respectively. We measured serum concentrations of serotonin, brain-derived neurotrophic factor, and ATP, which are associated with the development of depression. We found that the Xuefu Zhuyu granule significantly improved the angina pectoris-specific health status in patients after 12 weeks of treatment; specifically, it had a better curative effect on patients with depressive symptoms. Xuefu Zhuyu granule also significantly improved the chest stuffiness and heartache syndrome in patients with depressive symptoms (efficacy index is 61.24%, P < 0.05 versus baseline). Interestingly, Xuefu Zhuyu granule has been found to be more susceptible to improving ATP levels in patients with depressive symptoms, indicating that the improvement in serum ATP levels might account for the better efficacy of Xuefu Zhuyu granule in patients with depressive symptoms. Our data provide prospective evidence that Xuefu Zhuyu granule improves angina pectoris-specific health status through regulating Qi and promoting blood circulation. This trial is registered with ChiCTR-IOR-15006989.

scholarly journals Core outcome set for stable angina pectoris in traditional Chinese medicine (COS-SAP-TCM)

2021 ◽  
Vol 1 (1) ◽  
pp. 39-48
Author(s):  
Mingyan Zhang ◽  
Junhua Zhang ◽  
Hui Zi Chua ◽  
Rui Feng ◽  
Meijuan Lu ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Angina Pectoris ◽  
Traditional Chinese Medicine ◽  
Stable Angina ◽  
Core Outcome Set ◽  
Core Outcome ◽  
Stable Angina Pectoris ◽  
Outcome Set

scholarly journals Heart rate variability in patients with stable angina pectoris as a risk factor for adverse clinical prognosis: relationship with affective depressive symptoms

2020 ◽  
Vol 11 (4) ◽  
pp. 43-50
Author(s):  
A. O. Lobe ◽  
A. I. Chebotova ◽  
D. N. Ivanchenko ◽  
N. P. Dorofeeva ◽  
A. S. Pleskachev ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Depressive Symptoms ◽  
Treatment Group ◽  
Angina Pectoris ◽  
Stable Angina ◽  
Depressive Disorders ◽  
Stable Angina Pectoris ◽  
Clinical Prognosis ◽  
Affective Symptoms

Objective: to investigate the heart rate variability (HRV) parameters of patients with a stable angina pectoris depending of presence depressive disorders; to identify the influence of affective symptoms on the clinical outcome during 12 months of observation.Material and methods: there are 121 male patients included in research with a stable angina pectoris II – III functional classes, hospitalized for a drug treatment and planned percutaneous coronary intervention (PCI) with stenting. The severity of affective symptoms and HRV are being assessed.Results: patients with depressive symptoms in the conservative treatment group had low SDNN level; patients with psychoemotional disorders in the surgical treatment group had differences by all HRV parameters (SDNN, SDANN, SDNN, rMSSD pNN50). Clinically unfavorable outcome, including intermediate points such as increase in angina attacks, re-hospitalization, stent’s restenosis, were mostly registered during 12 months of observation in the groups with affective symptoms.Conclusions: presence of depressive symptoms of patients with stable angina pectoris is accompanied with low HRV parameters, which is connected with worsening of cardiac prognosis. 

scholarly journals POSSIBILITIES OF ENDOVASCULAR TREATMENT OF PATIENTS WITH INFRARENAL AORTIC OCCLUSION

2017 ◽  
Vol 8 (1) ◽  
pp. 25-29 ◽  
Author(s):  
N P Dorofeeva ◽  
D N Ivanchenko ◽  
O G Mashtalova ◽  
I E Kulikova ◽  
S A Chibineva ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Renal Function ◽  
Depressive Symptoms ◽  
Angina Pectoris ◽  
Endovascular Treatment ◽  
Stable Angina ◽  
Stable Angina Pectoris ◽  
Sf 36 ◽  
Reduced Kidney Function

Quality of life is one of the indicators for a comprehensive assessment of the patient’s condition. Depression and reduced kidney function can impair the quality of life. Cognitive impairmen taffects negatively on patients’ quality of life. We examined 47 patients with stable angina pectoris. It was found that the presence of depressive symptoms is associated with a reduction in the quality of life with using the SF-36 scale. Worsening renal function was also associated with the deterioration of quality of life and worsening of depressive symptoms. The cognitive dysfunction has progressed with decreasing renal function.

scholarly journals Clinical Evaluation of Compound Salvia Droplet Pills in the Treatment of Stable Angina Pectoris:Study Protocol for a Randomized Double-blind Control Trial

2018 ◽  
Author(s):  
Zhi Liu ◽  
Zhen Wang ◽  
Rui Gao ◽  
Hui Wang ◽  
Wenke Zheng ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Chinese Medicine ◽  
Angina Pectoris ◽  
Traditional Chinese Medicine ◽  
Clinical Efficacy ◽  
Stable Angina ◽  
Controlled Trial ◽  
Blood Stasis ◽  
Randomized Controlled ◽  
Enteric Coated

Abstract Background SAP (Stable Angina Pectoris, SAP) is a clinical syndrome characterized by acute and temporary myocardial ischemia and hypoxia due to an increase in the myocardial load resulting from a fixed severe stenosis of the coronary artery. Its’ characteristics include paroxysmal pressure pain or tightness in the prothorax, primarily retrosternal pain, which can radiate to the precordium and upper left ulna. It often occurs during physical exertion and lasts for several minutes. Traditional Chinese Medicine (TCM) has unique advantages in treating this disease due to holistic, dynamic and dialectical system of thought regarding life and diseases. Clinical efficacy is the basis for the survival and development of Traditional Chinese Medicine. Scientifically evaluating the clinical efficacy of such TCM treatments is of great importance for promoting its’ modernization and internationalization. In this study, we aimed to observe the therapeutic effects of Compound Salvia Droplet Pills on patients with SAP (Qi deficiency and blood stasis), as shown by a standardized clinical study on the treatment of SAP by means of supplementing qi and activating blood circulation by taking TCM treatments for CHD, thereby providing a practical and valuable clinical treatment approach. Methods A randomized, controlled trial was designed to evaluate the efficacy and safety of Compound Salvia Droplet Pills for the treatment of SAP. A proposed total of 60 patients with SAP (Qi deficiency and blood stasis type) are to be entered into the study. The patients shall be randomly assigned to treatment groups (compound Salvia Droplet Pills, 10 pills/time, 3 times a day, + aspirin enteric - coated tablets 100mg/time, once a day) or the control group (compound Salvia Droplet Pills mimetics, 10 pills/time, 3 times a day, + aspirin enteric - coated tablets 100mg/time, once a day), duration of 28 ±1, and follow-up for 14 ± 3 days. Primary outcome measures: angina pectoris symptom scores and TCM syndrome scores. Secondary outcome measures: ECG, incidence and mortality of cardiovascular events, etc. Discussion This is a randomized controlled trial for Compound Salvia Droplet Pills to treat SAP on the basis of conventional therapy, to preliminarily evaluate the efficacy in the treatment of patients with SAP (angina symptoms, signs and reducing the use of vasodilator drugs, etc.), and follows up on the short -term prognosis of patients to provide clinical evidence for the use of compound Salvia Droplet Pills in patients with SAP.

Sign in / Sign up

Export Citation Format

Share Document